In a report released today, Mani Foroohar from SVB Securities maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report), with a price target of $8.00. The company’s shares closed last Friday at $8.65.
Foroohar covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, Ionis Pharmaceuticals, and Bluebird Bio. According to TipRanks, Foroohar has an average return of -14.9% and a 38.29% success rate on recommended stocks.
Currently, the analyst consensus on Recursion Pharmaceuticals is a Moderate Buy with an average price target of $19.67.
See Insiders’ Hot Stocks on TipRanks >>
Based on Recursion Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $13.05 million and a GAAP net loss of $60.45 million. In comparison, last year the company earned a revenue of $2.5 million and had a GAAP net loss of $47.43 million
Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RXRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Read More on RXRX:
